Celgene Release: Oral OTEZLA® (Apremilast) Demonstrated Clinically Meaningful And Sustained Improvements In Skin, Nail And Scalp Of Adult Patients With Moderate To Severe Plaque Psoriasis
Published: Mar 24, 2014
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today released new research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.
Help employers find you! Check out all the jobs and post your resume.